# A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

> **NCT04075747** · PHASE1 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CPX-351
- **DRUG:** Venetoclax
- **DRUG:** Midostaurin
- **DRUG:** Enasidenib

## Key facts

- **NCT ID:** NCT04075747
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-02
- **Primary completion:** 2022-02-07
- **Final completion:** 2023-09-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04075747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04075747, "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04075747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*